Learn
GLP-1 prices in 2026: TrumpRx, NovoCare, LillyDirect and Medicare
By the Everlon founding team ·
If the last time you priced a GLP-1 was 2024 or 2025, the numbers you remember are out of date. On November 6, 2025 the White House announced pricing agreements with Novo Nordisk and Eli Lilly, and during 2026 the self-pay prices of brand-name GLP-1 medications fell from four figures to a few hundred dollars a month. This page lists what the manufacturers charge today, what Medicare now covers, and how to compare your options, including where a compounded program fits and where it doesn't.
What changed
- TrumpRx.gov launched on February 5, 2026. It lists the manufacturers' self-pay prices for people with a valid prescription. For Ozempic®, Wegovy® and the Wegovy® pill it gives you a coupon to present at a pharmacy; Zepbound® and Foundayo™ orders go to Lilly's LillyDirect pharmacy service. Each price is marked as an out-of-pocket price, not an insurance price.
- Two brand-name GLP-1 pills are now FDA-approved. The Wegovy® pill (oral semaglutide) was approved on December 22, 2025, and Foundayo™ (orforglipron) on April 1, 2026.
- Medicare's GLP-1 Bridge started on July 1, 2026 and runs through December 31, 2027. It covers certain GLP-1 medications for a $50 copay per one-month supply, for people with a Part D plan who meet the eligibility criteria, with prior authorization.
Self-pay prices, by dose (checked September 25, 2026)
| Medication | Self-pay price per month | Where | Conditions |
|---|---|---|---|
| Wegovy® injection (semaglutide) | $199 for a new patient's first two monthly fills at 0.25 mg or 0.5 mg, then $349; $349 at 1 mg, 1.7 mg and 2.4 mg; $399 for Wegovy® HD 7.2 mg | NovoCare Pharmacy, TrumpRx | The $199 offer runs through December 31, 2026 |
| Ozempic® (semaglutide) | $199 for a new patient's first two monthly fills at 0.25 mg or 0.5 mg, then $349; $349 at 1 mg; $499 at 2 mg | NovoCare Pharmacy, TrumpRx | Ozempic® is approved for type 2 diabetes. The $199 offer runs through December 31, 2026 |
| Wegovy® pill (semaglutide) | $149 at 1.5 mg; $199 at 4 mg; $299 at 9 mg and 25 mg | NovoCare Pharmacy, TrumpRx | One month is 30 tablets |
| Zepbound® (tirzepatide), vial or KwikPen® | $299 at 2.5 mg; $399 at 5 mg; $449 at 7.5 mg and above if each refill is bought within 45 days of the last delivery | LillyDirect, TrumpRx | Without an on-time refill: $499 at 7.5 mg, $699 at 10 mg to 15 mg. Savings end December 31, 2026 |
| Foundayo™ pill (orforglipron) | $149 at 0.8 mg; $149 at 2.5 mg and $199 at 5.5 mg for now; higher doses cost more | LillyDirect, TrumpRx | The 2.5 mg and 5.5 mg prices are temporary, through December 31, 2026. Check LillyDirect for higher doses |
| Medicare GLP-1 Bridge (if eligible) | $50 copay per one-month supply | Your Part D plan | Covers Foundayo™, Wegovy® (injection or pill) and Zepbound® KwikPen®. Prior authorization required |
Prices change, vary by dose and have conditions. Check the official pages in the Sources list before you decide anything.
List prices, what insurers are billed before rebates, are still over $1,000 a month: TrumpRx shows $1,349.02 for Wegovy® and $1,027.51 for Ozempic®. Novo Nordisk has announced a list price of $675 a month for both from January 1, 2027, and says that change does not affect its self-pay prices.
The fine print that decides your real cost
The self-pay programs sell the medication, not the care. TrumpRx and the manufacturer programs need a valid prescription, but they don't evaluate you, change your dose or answer questions later. You bring your own prescriber: your doctor, or a telehealth service you pay separately. When you compare prices, add everything up: medication, prescriber visits, follow-up and shipping.
Most brand prices change with the dose. The table shows it for every brand. If your prescriber changes your dose, your price can change with it, so check the price at the dose you would actually be taking, not only the starting one.
Several of the lowest prices are temporary. The $199 first fills for Wegovy® and Ozempic®, the lower Zepbound® refill prices and the reduced Foundayo™ prices all end December 31, 2026, unless the manufacturers extend them. Zepbound®'s lower prices at 7.5 mg and above also depend on refilling within 45 days.
Eligibility has fine print. The Novo Nordisk self-pay pages exclude people enrolled in government healthcare programs. The Medicare Bridge has its own criteria, listed on Medicare.gov.
Who each route fits
- You have insurance or Medicare Part D: check your coverage first. If your plan covers a brand-name GLP-1, a copay usually beats any cash price. Ask your plan directly.
- You're paying cash and want an FDA-approved brand: TrumpRx, NovoCare Pharmacy or LillyDirect, at the prices above, plus a prescriber you arrange and pay for yourself.
- You're paying cash and want one price that includes the care: all-in telehealth programs.
At Everlon, semaglutide is $129 first month, then $249/mo from month 2, if prescribed. Tirzepatide is $315/mo, if prescribed. The provider evaluation, check-ins, dose adjustments and standard shipping are included, the monthly price doesn't change with your dose, and you'll only be charged if treatment is prescribed.
The medication prescribed through Everlon is compounded by a state-licensed 503A pharmacy, and that is a real difference, not a footnote. Compounded medications are not FDA-approved. For many people, especially anyone with coverage, a brand-name product is the better answer.
Questions to ask before you pay anyone
- Is this price for the medication only, or does it include the prescriber and follow-up care?
- What will it cost at the dose I'd actually be on? Does the price change with the dose?
- Is this an introductory price, and when does it end?
- Who is evaluating me, and can they decline to prescribe? (If nobody can say no, walk away.)
- Which pharmacy fills it, and is it licensed in my state?
- What are the cancellation and renewal terms?
FAQ
Is TrumpRx a pharmacy? No. TrumpRx.gov lists the manufacturers' self-pay prices and sends you on, either to a pharmacy with a coupon or to LillyDirect to order. You still need a prescription from a licensed prescriber.
Does Medicare cover weight-loss medication now? For some people. The Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Foundayo™, Wegovy® and Zepbound® KwikPen® for a $50 copay per one-month supply, for eligible people with a Part D plan, with prior authorization. Medicare.gov lists who qualifies.
Why would anyone still choose a compounded program? Mostly for one bundled price that includes the care, at the same monthly price whatever the dose. It is a trade-off: compounded medications are not FDA-approved, and a brand-name product may be the better choice, especially if you have coverage.
Will these prices last? Several won't in their current form: the introductory and temporary prices above end December 31, 2026, unless extended. We re-check this page against the official sources and update it when the numbers move.
Sources
- Fact sheet: most-favored-nation pricing agreements (November 6, 2025) — The White House, accessed 2026-09-25
- Fact sheet: TrumpRx.gov launch (February 5, 2026) — The White House, accessed 2026-09-25
- Wegovy® pen — TrumpRx.gov, accessed 2026-09-25
- Ozempic® — TrumpRx.gov, accessed 2026-09-25
- Wegovy® pill — TrumpRx.gov, accessed 2026-09-25
- Zepbound® — TrumpRx.gov, accessed 2026-09-25
- Foundayo™ — TrumpRx.gov, accessed 2026-09-25
- Wegovy® self-pay offer — NovoCare Pharmacy (Novo Nordisk), accessed 2026-09-25
- Wegovy® pill broadly available, with launch pricing (January 5, 2026) — Novo Nordisk, accessed 2026-09-25
- FDA approves the Wegovy® pill (December 22, 2025) — Novo Nordisk, accessed 2026-09-25
- US list-price reduction for Wegovy® and Ozempic® (February 24, 2026) — Novo Nordisk, accessed 2026-09-25
- Zepbound® coverage, affordability and savings — Eli Lilly, accessed 2026-09-25
- FDA approves Foundayo™ (April 1, 2026) — Eli Lilly, accessed 2026-09-25
- Weight loss drugs — Medicare.gov, accessed 2026-09-25
- Medicare GLP-1 Bridge — CMS, accessed 2026-09-25
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Zepbound® and KwikPen® are registered trademarks, and Foundayo™ is a trademark, of Eli Lilly and Company. NovoCare, LillyDirect and TrumpRx are programs of their respective owners. Everlon is not affiliated with or endorsed by Novo Nordisk, Eli Lilly or TrumpRx.gov.
Where to go next
Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.
Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.